医学临床研究
   Jul. 13, 2025    Home  |  About Journal  |  Editorial Board  |  Instruction  |  Subscribe  |  Advertisement  |  Messages Board  |  Contact Us  |  中文
JOURNAL OF CLINICAL RESEARCH  2021, Vol. 38 Issue (2): 269-271    DOI: 10.3969/j.issn.1671-7171.2021.02.032
Current Issue | Archive | Adv Search |
Clinical Efficacy and Safety of Radiofrequency Ablation Combined with DC-CIK Immunotherapy for Advanced Primary Liver Cancer
WU Wei
Yangpu hospital,Tongji University, Shanghai 200092
Download: PDF (1163 KB)   HTML (0 KB) 
Export: BibTeX | EndNote (RIS)      
Abstract  【Objective】 To study the efficacy and safety of radiofrequency ablation of (RFA) combined with dendritic cells-cytokines-induced killer cells (DC-CIK) in the treatment of advanced primary liver cancer. 【Methods】 A total of 86 patients with advanced primary liver cancer in our hospital from January 2018 to June 2019 were selected and randomly divided into control group (treated with RFA) and observation group (treated with RFA combined with DC-CIK immunotherapy), 43 cases in each group. The serum indexes, immune function, liver function and survival of patients were observed before and after treatment, and the short-term efficacy and incidence of adverse reactions were compared between the two groups.【Results】 The disease control rate of the observation group was 79.07% (34/43), which was significantly higher than 41.86% (18/43) of the control group (P<0.05). After treatment, the levels of serum alpha fetoprotein (AFP), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF) in the observation group were significantly decreased (P<0.05), and were lower than those in the control group (P<0.05); while the levels of serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) and total bilirubin (TBIL) in the observation group were higher than those before treatment, and were lower than those in the control group, the difference was statistically significant (P<0.05).The CD3+、CD4+、CD4+/CD8+ of peripheral blood T cell subsets in the observation group were significantly higher than those before treatment, and were significantly higher than those in the control group, the difference was statistically significant (P<0.05). The incidence of adverse reactions in the observation group was 27.91% (12/43), which was higher than 23.26% (10/43) in the control group, and the difference was not statistically significant (P>0.05). The 1-year and 3-year survival rates of the observation group were significantly higher than those of the control group (all P<0.05).【Conclusion】 RFA combined with DC-CIK immunotherapy is effective in the treatment of patients with advanced primary liver cancer. It can reduce the level of serum tumor markers, improve the immune function, reduce the degree of liver function damage, prolong the survival rate, and has good safety, which is worthy of clinical application.
Key wordsLiver Neoplasms/TH      Liver Neoplasms/IM      Catheter Ablation      Treatment Outcome     
Received: 18 July 2019     
:  R735.7  
Service
E-mail this article
Add to my bookshelf
Add to citation manager
E-mail Alert
RSS
Articles by authors
WU Wei
Cite this article:   
WU Wei. Clinical Efficacy and Safety of Radiofrequency Ablation Combined with DC-CIK Immunotherapy for Advanced Primary Liver Cancer[J]. JOURNAL OF CLINICAL RESEARCH, 2021, 38(2): 269-271.
URL:  
http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2021.02.032     OR     http://journal07.magtech.org.cn/yxlcyj/EN/Y2021/V38/I2/269
Copyright © Editorial Board of JOURNAL OF CLINICAL RESEARCH
Supported by:Beijing Magtech